TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s stock price rose 1.4% on Tuesday . The company traded as high as $2.86 and last traded at $2.81. Approximately 158,324 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 32,220,806 shares. The stock had previously closed at $2.77.
TNF Pharmaceuticals Trading Up 1.4%
The company has a market capitalization of $5.19 million, a PE ratio of -0.01 and a beta of 2.04. The firm has a fifty day moving average of $3.42 and a two-hundred day moving average of $3.71.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Read More
- Five stocks we like better than TNF Pharmaceuticals
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
